These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 32538547)

  • 21. α-Synuclein in blood cells differentiates Parkinson's disease from healthy controls.
    Abd Elhadi S; Grigoletto J; Poli M; Arosio P; Arkadir D; Sharon R
    Ann Clin Transl Neurol; 2019 Dec; 6(12):2426-2436. PubMed ID: 31742923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
    Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
    J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 3,4-Dihydroxyphenylacetaldehyde Is More Efficient than Dopamine in Oligomerizing and Quinonizing
    Jinsmaa Y; Isonaka R; Sharabi Y; Goldstein DS
    J Pharmacol Exp Ther; 2020 Feb; 372(2):157-165. PubMed ID: 31744850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extracellular α-synuclein enters dopaminergic cells by modulating flotillin-1-assisted dopamine transporter endocytosis.
    Kobayashi J; Hasegawa T; Sugeno N; Yoshida S; Akiyama T; Fujimori K; Hatakeyama H; Miki Y; Tomiyama A; Kawata Y; Fukuda M; Kawahata I; Yamakuni T; Ezura M; Kikuchi A; Baba T; Takeda A; Kanzaki M; Wakabayashi K; Okano H; Aoki M
    FASEB J; 2019 Sep; 33(9):10240-10256. PubMed ID: 31211923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. α-Synuclein protects against manganese neurotoxic insult during the early stages of exposure in a dopaminergic cell model of Parkinson's disease.
    Harischandra DS; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
    Toxicol Sci; 2015 Feb; 143(2):454-68. PubMed ID: 25416158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. α-Synuclein stimulation of monoamine oxidase-B and legumain protease mediates the pathology of Parkinson's disease.
    Kang SS; Ahn EH; Zhang Z; Liu X; Manfredsson FP; Sandoval IM; Dhakal S; Iuvone PM; Cao X; Ye K
    EMBO J; 2018 Jun; 37(12):. PubMed ID: 29769405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of fragile X mental retardation protein precedes Lewy pathology in Parkinson's disease.
    Tan Y; Sgobio C; Arzberger T; Machleid F; Tang Q; Findeis E; Tost J; Chakroun T; Gao P; Höllerhage M; Bötzel K; Herms J; Höglinger G; Koeglsperger T
    Acta Neuropathol; 2020 Feb; 139(2):319-345. PubMed ID: 31768670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Total and Proteinase K-Resistant α-Synuclein Levels in Erythrocytes, Determined by their Ability to Bind Phospholipids, Associate with Parkinson's Disease.
    Abd-Elhadi S; Honig A; Simhi-Haham D; Schechter M; Linetsky E; Ben-Hur T; Sharon R
    Sci Rep; 2015 Jun; 5():11120. PubMed ID: 26068055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach.
    Bazzu G; Calia G; Puggioni G; Spissu Y; Rocchitta G; Debetto P; Grigoletto J; Zusso M; Migheli R; Serra PA; Desole MS; Miele E
    CNS Neurol Disord Drug Targets; 2010 Aug; 9(4):482-90. PubMed ID: 20522009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinct pattern of enteric phospho-alpha-synuclein aggregates and gene expression profiles in patients with Parkinson's disease.
    Barrenschee M; Zorenkov D; Böttner M; Lange C; Cossais F; Scharf AB; Deuschl G; Schneider SA; Ellrichmann M; Fritscher-Ravens A; Wedel T
    Acta Neuropathol Commun; 2017 Jan; 5(1):1. PubMed ID: 28057070
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microglia affect α-synuclein cell-to-cell transfer in a mouse model of Parkinson's disease.
    George S; Rey NL; Tyson T; Esquibel C; Meyerdirk L; Schulz E; Pierce S; Burmeister AR; Madaj Z; Steiner JA; Escobar Galvis ML; Brundin L; Brundin P
    Mol Neurodegener; 2019 Aug; 14(1):34. PubMed ID: 31419995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma Extracellular Vesicle α-Synuclein Level in Patients with Parkinson's Disease.
    Chung CC; Chan L; Chen JH; Hung YC; Hong CT
    Biomolecules; 2021 May; 11(5):. PubMed ID: 34067663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma alpha-synuclein levels in patients with Parkinson's disease: a systematic review and meta-analysis.
    Bougea A; Stefanis L; Paraskevas GP; Emmanouilidou E; Vekrelis K; Kapaki E
    Neurol Sci; 2019 May; 40(5):929-938. PubMed ID: 30715632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decrease in plasma levels of α-synuclein is evident in patients with Parkinson's disease after elimination of heterophilic antibody interference.
    Ishii R; Tokuda T; Tatebe H; Ohmichi T; Kasai T; Nakagawa M; Mizuno T; El-Agnaf OM
    PLoS One; 2015; 10(4):e0123162. PubMed ID: 25849645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease.
    Benskey MJ; Perez RG; Manfredsson FP
    J Neurochem; 2016 May; 137(3):331-59. PubMed ID: 26852372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of an Alternatively Spliced α-Synuclein Isoform That Generates a 41-Amino Acid N-Terminal Truncated Peptide, 41-syn: Role in Dopamine Homeostasis.
    Vinnakota RL; Yedlapudi D; Manda KM; Bhamidipati K; Bommakanti KT; RangaLakshmi GS; Kalivendi SV
    ACS Chem Neurosci; 2018 Dec; 9(12):2948-2958. PubMed ID: 29996045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 3,4-dihydroxyphenylacetaldehyde: a potential target for neuroprotective therapy in Parkinson's disease.
    Burke WJ
    Curr Drug Targets CNS Neurol Disord; 2003 Apr; 2(2):143-8. PubMed ID: 12769806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease.
    Majbour NK; Vaikath NN; van Dijk KD; Ardah MT; Varghese S; Vesterager LB; Montezinho LP; Poole S; Safieh-Garabedian B; Tokuda T; Teunissen CE; Berendse HW; van de Berg WD; El-Agnaf OM
    Mol Neurodegener; 2016 Jan; 11():7. PubMed ID: 26782965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dopamine and the dopamine oxidation product 5,6-dihydroxylindole promote distinct on-pathway and off-pathway aggregation of alpha-synuclein in a pH-dependent manner.
    Pham CL; Leong SL; Ali FE; Kenche VB; Hill AF; Gras SL; Barnham KJ; Cappai R
    J Mol Biol; 2009 Apr; 387(3):771-85. PubMed ID: 19361420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Therapeutic Implications of Tea Polyphenols Against Dopamine (DA) Neuron Degeneration in Parkinson's Disease (PD).
    Zhou ZD; Xie SP; Saw WT; Ho PGH; Wang H; Lei Z; Yi Z; Tan EK
    Cells; 2019 Aug; 8(8):. PubMed ID: 31426448
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.